Incidence of key bevacizumab-related adverse events in selected phase III randomized clinical trials.
Abbreviations: ATE, arterial thromboembolism; BV, bevacizumab; GIP, gastrointestinal perforation; HTN, hypertension; MAX, Mitomycin Avastin® Xeloda.